Every Form 4 that Clene Inc. (CLNN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLNN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLNN filings page.
Clene Inc. director David J. Matlin reported buying units of Clene stock and warrants in a private transaction that closed on January 13, 2026. He purchased 33,333 shares of common stock at a unit price of $6.50, with each unit including one share plus a Series A and a Series B warrant. Following this purchase, he held 477,824 common shares directly.
Matlin also acquired Series A warrants for 40,000 shares and Series B warrants for 93,333 shares, each initially exercisable at $6.00 per share. The Series A warrant exercise price can increase to $7.00 per share based on FDA action-date announcements or if the stock’s volume-weighted average price reaches $10.00 on a specified date. The Series B warrant exercise price can increase to $12.50 or $10.00 per share depending on FDA approval of CNM-Au8 in ALS and future volume-weighted average price thresholds.
Symbiosis II, LLC, an entity associated with 10% owner Chidozie Ugwumba, reported multiple sales of Clene Inc. common stock. On January 8, 2026, it sold 3,195 shares at $6.09 per share, leaving 750,367 shares indirectly owned. On January 9, 2026, it sold 9,075 shares at $6.27 per share, leaving 741,292 shares indirectly owned. On January 12, 2026, it sold 32,705 shares at $5.50 per share, leaving 708,587 shares of Clene common stock held indirectly through Symbiosis II, LLC.
Clene Inc. reported insider share sales by a 10% owner associated with Ugwumba Chidozie, disclosed in a Form 4 filing. The transactions involved indirect holdings of Clene common stock through Symbiosis II, LLC.
Symbiosis II, LLC sold 5,869 shares at $5.87 on January 5, 2026, 3,111 shares at $6.04 on January 6, 2026, and 3,938 shares at $6.29 on January 7, 2026. Following the last sale, Symbiosis II, LLC indirectly held 753,562 shares of Clene common stock.
Clene Inc. reported insider selling of common stock by a 10% owner in December 2025. The Form 4 shows a series of open-market sales coded "S" from 12/03/2025 through 12/18/2025, with individual trades ranging from 2,884 to 72,748 shares at prices between $5.70 and $7.86 per share. All transactions involved Clene common stock held indirectly through Symbiosis II, LLC.
After these sales, the reporting person beneficially owned 393,150 shares of Clene common stock, held indirectly via Symbiosis II, LLC as of 12/18/2025. No derivative securities transactions were reported, as the derivative securities table is blank.
Clene Inc. (CLNN) disclosed a director stock option grant. On 11/13/2025, the director received an option for 1,893 shares of common stock at an exercise price of $7.30 per share under the Amended 2020 Stock Plan. The option vests immediately upon grant and expires on 11/12/2035.
Following the transaction, the filing shows 1,893 derivative securities beneficially owned, held in direct ownership.
Clene Inc. (CLNN) reported a director equity award on Form 4. On November 13, 2025, the director received a stock option covering 2,438 shares of common stock at an exercise price of $7.30 per share under the Clene Inc. Amended 2020 Stock Plan. The option vests immediately upon grant and carries an expiration date of November 12, 2035.
The filing classifies the transaction as an acquisition of derivative securities and lists direct ownership following the grant.
Clene Inc. (CLNN) reported an insider equity award. A director filed a Form 4 disclosing a stock option grant for 2,887 shares of common stock at an exercise price of $7.30 per share on November 13, 2025. The options vest immediately upon grant under the Clene Inc. Amended 2020 Stock Plan and carry an expiration date of November 12, 2035. Following the transaction, the filing shows 2,887 derivative securities beneficially owned with direct ownership.
Clene Inc. (CLNN) reported a stock-based compensation award to one of its directors. On November 13, 2025, the director received a stock option covering 2,816 shares of Clene common stock under the company’s Amended 2020 Stock Plan. The option has an exercise price of $7.30 per share and vests immediately, meaning the director can exercise it right away, subject to plan terms. The option is scheduled to expire on November 12, 2035 if not exercised.
Clene Inc. (CLNN) reported a routine insider transaction: a director received a stock option grant for 1,893 shares on 11/13/2025 under the Amended 2020 Stock Plan at an exercise price of $7.30 per share.
The options vest immediately upon grant and expire on 11/12/2035. Ownership of the derivative securities is reported as direct.